Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-trace').style.display = (document.getElementById('cakeErr682768f6188e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682768f6188e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-code').style.display = (document.getElementById('cakeErr682768f6188e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-context').style.display = (document.getElementById('cakeErr682768f6188e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682768f6188e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682768f6188e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20100,
		&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20241,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20100,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,novartis,Cancer,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20100,
	&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20241,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20100
$metaTitle = &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;
$metaKeywords = &#039;patents,novartis,Cancer,Health,medicines&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Landmark verdict gives big boost to cancer patients-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify">&nbsp;</p><p align="justify"><em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em></p><p align="justify">In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.</p><p align="justify">The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.</p><p align="justify">Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.</p><p align="justify">Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.</p><p align="justify">A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;</p><p align="justify">The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.</p><p align="justify">The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.</p><p align="justify">The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-trace').style.display = (document.getElementById('cakeErr682768f6188e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682768f6188e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-code').style.display = (document.getElementById('cakeErr682768f6188e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-context').style.display = (document.getElementById('cakeErr682768f6188e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682768f6188e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682768f6188e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20100,
		&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20241,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20100,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,novartis,Cancer,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20100,
	&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20241,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20100
$metaTitle = &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;
$metaKeywords = &#039;patents,novartis,Cancer,Health,medicines&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Landmark verdict gives big boost to cancer patients-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify">&nbsp;</p><p align="justify"><em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em></p><p align="justify">In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.</p><p align="justify">The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.</p><p align="justify">Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.</p><p align="justify">Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.</p><p align="justify">A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;</p><p align="justify">The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.</p><p align="justify">The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.</p><p align="justify">The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-trace').style.display = (document.getElementById('cakeErr682768f6188e1-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr682768f6188e1-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-code').style.display = (document.getElementById('cakeErr682768f6188e1-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr682768f6188e1-context').style.display = (document.getElementById('cakeErr682768f6188e1-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr682768f6188e1-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr682768f6188e1-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20100,
		&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20241,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20100,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;patents,novartis,Cancer,Health,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20100,
	&#039;title&#039; =&gt; &#039;Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20241,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20100
$metaTitle = &#039;LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan&#039;
$metaKeywords = &#039;patents,novartis,Cancer,Health,medicines&#039;
$metaDesc = &#039;
-The Hindu


&amp;nbsp;


Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;Supreme Court rejects Novartis&#039; plea for patent; green signal for cheaper generic drugs&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The judgment allows suppliers to continue making generic copies of Swiss firm Novartis&#039; Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Observers say that the Court&#039;s judgment sets a precedent against the practice of &amp;quot;evergreening&amp;quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &amp;quot;evergreening&amp;quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &amp;quot;beta crystalline&amp;quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &amp;quot;We firmly reject the appellant&#039;s case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The Bench said that the patent application contains a &amp;quot;clear and unambiguous averment&amp;quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &amp;quot;are possessed&amp;quot; by the original version.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The court said that the Patents (Amendment) Act, 2005 established that the &amp;quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&amp;quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &amp;quot;solubility&amp;quot;, saying the &amp;quot;efficacy&amp;quot; of this property over its predecessor chemical is not established. &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan | Im4change.org</title>
    <meta name="description" content="
-The Hindu


&nbsp;


Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Landmark verdict gives big boost to cancer patients-J Venkatesan</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu</div><p align="justify">&nbsp;</p><p align="justify"><em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em></p><p align="justify">In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.</p><p align="justify">The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.</p><p align="justify">Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.</p><p align="justify">Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.</p><p align="justify">A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;</p><p align="justify">The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.</p><p align="justify">The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.</p><p align="justify">The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20100,
		'title' => 'Landmark verdict gives big boost to cancer patients-J Venkatesan',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
&nbsp;
</p>
<p align="justify">
<em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em>
</p>
<p align="justify">
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
</p>
<p align="justify">
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
</p>
<p align="justify">
Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
</p>
<p align="justify">
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
</p>
<p align="justify">
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;
</p>
<p align="justify">
The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.
</p>
<p align="justify">
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
</p>
<p align="justify">
The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. 
</p>',
		'credit_writer' => 'The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20241,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20100,
	'metaTitle' => 'LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan',
	'metaKeywords' => 'patents,novartis,Cancer,Health,medicines',
	'metaDesc' => '
-The Hindu


&nbsp;


Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...',
	'disp' => '<div align="justify">-The Hindu</div><p align="justify">&nbsp;</p><p align="justify"><em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em></p><p align="justify">In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.</p><p align="justify">The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.</p><p align="justify">Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.</p><p align="justify">Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.</p><p align="justify">A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;</p><p align="justify">The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.</p><p align="justify">The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.</p><p align="justify">The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20100,
	'title' => 'Landmark verdict gives big boost to cancer patients-J Venkatesan',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu
</div>
<p align="justify">
&nbsp;
</p>
<p align="justify">
<em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em>
</p>
<p align="justify">
In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.
</p>
<p align="justify">
The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.
</p>
<p align="justify">
Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.
</p>
<p align="justify">
Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.
</p>
<p align="justify">
A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;
</p>
<p align="justify">
The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.
</p>
<p align="justify">
The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.
</p>
<p align="justify">
The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. 
</p>',
	'credit_writer' => 'The Hindu, 1 April, 2013, http://www.thehindu.com/news/national/landmark-verdict-gives-big-boost-to-cancer-patients/article4569056.ece?homepage=true',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'landmark-verdict-gives-big-boost-to-cancer-patients-j-venkatesan-20241',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20241,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20100
$metaTitle = 'LATEST NEWS UPDATES | Landmark verdict gives big boost to cancer patients-J Venkatesan'
$metaKeywords = 'patents,novartis,Cancer,Health,medicines'
$metaDesc = '
-The Hindu


&nbsp;


Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs


In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a...'
$disp = '<div align="justify">-The Hindu</div><p align="justify">&nbsp;</p><p align="justify"><em>Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs</em></p><p align="justify">In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention.</p><p align="justify">The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug.</p><p align="justify">Observers say that the Court's judgment sets a precedent against the practice of &quot;evergreening&quot; - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other &quot;evergreening&quot; patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs.</p><p align="justify">Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a &quot;beta crystalline&quot; salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court.</p><p align="justify">A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: &quot;We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent.&quot;</p><p align="justify">The Bench said that the patent application contains a &quot;clear and unambiguous averment&quot; that all the therapeutic qualities of the modified form, for which the patent was applied, &quot;are possessed&quot; by the original version.</p><p align="justify">The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy.</p><p align="justify">The court said that the Patents (Amendment) Act, 2005 established that the &quot;mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance&quot; is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better &quot;solubility&quot;, saying the &quot;efficacy&quot; of this property over its predecessor chemical is not established. </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Landmark verdict gives big boost to cancer patients-J Venkatesan

-The Hindu   Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to fight chronic blood cancer effectively. While the Novartis drug costs more than Rs 1 lakh per month, with doctors often advising patients to take it lifelong, the generic equivalents cost less than one-tenth. The ruling would be a relief to some 300,000 patients in India currently taking the drug. Observers say that the Court's judgment sets a precedent against the practice of "evergreening" - a strategy through which drug manufacturers introduce modifications of drugs to extend the five-year patents on them. They say that other "evergreening" patent applications could be rejected citing this judgment, helping to keep many life-saving drugs out of the patent regime and pushing down costs. Glivec is the brand name of Imatinib. Novartis had applied for a patent for a modification of this drug, a "beta crystalline" salt form of Imatinib Mesylate or IM, which it said could be better absorbed by the body - by up to 30% more. After its patent application was rejected by the Patent office, Novartis moved the Intellectual Property Board, Chennai. The Board rejected the claim, but gave certain findings favourable to the company. Instead of filing an appeal before the Madras High Court, Novartis moved the Supreme Court. A Bench of Supreme Court Justices Aftab Alam and Ranjana Desai said: "We firmly reject the appellant's case that Imatinib Mesylate is a new product and the outcome of an invention beyond the Zimmermann [original] patent." The Bench said that the patent application contains a "clear and unambiguous averment" that all the therapeutic qualities of the modified form, for which the patent was applied, "are possessed" by the original version. The court held that patents can be granted only for medicines that are truly new and innovative. For new forms and new uses of existing medicines, patent applicants should prove improved efficacy. The court said that the Patents (Amendment) Act, 2005 established that the "mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" is not an invention - for the purpose of patenting. The Bench also dismissed the argument that the modified form had better "solubility", saying the "efficacy" of this property over its predecessor chemical is not established.